GSK, Genmab Submit NDA For Arzerra To Treat Chronic Lymphocytic Leukemia

Realtime

Geld

Brief

Zeit

20,321

20,731

24.05.

20,412

20,464

24.05.

GSK, Genmab Submit NDA For Arzerra To Treat Chronic Lymphocytic Leukemia

LONDON (dpa-AFX) - Genmab A/S (GNMSF.PK) and GlaxoSmithKline (GSK, GSK.L) announced the submission of a New Drug Application to the Japanese Ministry of Health, Labor and Welfare for Arzerra (ofatumumab) for the treatment of chronic lymphocytic leukemia.

'This marks another important achievement in our collaboration with GSK for Arzerra,' said Jan van de Winkel, Chief Executive Officer of Genmab. 'The global commercialization of Arzerra continues as planned.'

Today's announcement does not affect Genmab's financial guidance for 2012.

Copyright RTT News/dpa-AFX

Zeit	Aktuelle Nachrichten
17.05.	Genmab A/S: Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
	Company Announcement -- Genentech and Biogen Idec have filed for re-hearing in the United States Copenhagen, Denmark; May 17, 2013 - Genmab A/S (OMX: GEN) announced today that Genentech and Biogen... Mehr lesen zu: Genmab A/S: Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
17.05.	NASDAQ OMX Copenhagen A/S: Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise
	The share capital of Genmab A/S has been increased. The admittance to trading and official listing will take effect on 21 May 2013 in the ISIN below. We refer to the announcements published by Genmab. ISIN:... Mehr lesen zu: NASDAQ OMX Copenhagen A/S: Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise
16.05.	Genmab A/S: Articles of Association for Genmab A/S
	Genmab A/S has published its Articles of Association dated May 15, 2013. The Articles of Association can be found on Genmab's website: http://ir.genmab.com/releases.cfm Contact: Rachel Curtis Gravesen... Mehr lesen zu: Genmab A/S: Articles of Association for Genmab A/S
16.05.	Genmab A/S: Daratumumab Data to be Presented at ASCO Annual Meeting
	Media Release -- Latest from daratumumab Phase I/II study in relapsed/refractory multiple myeloma -- Pre-clinical data from HuMax-TF-ADC program -- Abstracts available online at ASCO website Copenhagen... Mehr lesen zu: Genmab A/S: Daratumumab Data to be Presented at ASCO Annual Meeting
15.05.	Genmab A/S: Report Pursuant to Section 28a of the Danish Securities Trading Act
	Company Announcement Copenhagen, Denmark; May 15, 2013 - Pursuant to Section 28a of the Danish Securities Trading Act, Genmab A/S (OMX: GEN) hereby, on behalf of managerial employees, makes public... Mehr lesen zu: Genmab A/S: Report Pursuant to Section 28a of the Danish Securities Trading Act

Zeit

Aktuelle Nachrichten

17.05.

Genmab A/S: Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Company Announcement -- Genentech and Biogen Idec have filed for re-hearing in the United States Copenhagen, Denmark; May 17, 2013 - Genmab A/S (OMX: GEN) announced today that Genentech and Biogen...
Mehr lesen zu:
Genmab A/S: Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

17.05.

NASDAQ OMX Copenhagen A/S: Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise

The share capital of Genmab A/S has been increased. The admittance to trading and official listing will take effect on 21 May 2013 in the ISIN below. We refer to the announcements published by Genmab. ISIN:...
Mehr lesen zu:
NASDAQ OMX Copenhagen A/S: Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise

16.05.

Genmab A/S: Articles of Association for Genmab A/S

Genmab A/S has published its Articles of Association dated May 15, 2013. The Articles of Association can be found on Genmab's website: http://ir.genmab.com/releases.cfm Contact: Rachel Curtis Gravesen...
Mehr lesen zu:
Genmab A/S: Articles of Association for Genmab A/S

16.05.

Genmab A/S: Daratumumab Data to be Presented at ASCO Annual Meeting

Media Release -- Latest from daratumumab Phase I/II study in relapsed/refractory multiple myeloma -- Pre-clinical data from HuMax-TF-ADC program -- Abstracts available online at ASCO website Copenhagen...
Mehr lesen zu:
Genmab A/S: Daratumumab Data to be Presented at ASCO Annual Meeting

15.05.

Genmab A/S: Report Pursuant to Section 28a of the Danish Securities Trading Act

Company Announcement Copenhagen, Denmark; May 15, 2013 - Pursuant to Section 28a of the Danish Securities Trading Act, Genmab A/S (OMX: GEN) hereby, on behalf of managerial employees, makes public...
Mehr lesen zu:
Genmab A/S: Report Pursuant to Section 28a of the Danish Securities Trading Act

Zeit	Aktuelle Nachrichten
24.05.	Glaxo Alleges Errors In Nissen's Critique Of FDA's Handling Of Avandia
	Mehr lesen zu: Glaxo Alleges Errors In Nissen's Critique Of FDA's Handling Of Avandia
23.05.	GSK flu shot may raise adult narcolepsy risk -Finnish scientists
	Mehr lesen zu: GSK flu shot may raise adult narcolepsy risk -Finnish scientists
23.05.	GSK, US HHS team up to develop drugs against antibiotic resistance and bioterrorism
	Mehr lesen zu: GSK, US HHS team up to develop drugs against antibiotic resistance and bioterrorism
22.05.	U.S. Gives Glaxo Up To $200 Million for Antibiotic Research
	Mehr lesen zu: U.S. Gives Glaxo Up To $200 Million for Antibiotic Research
22.05.	GlaxoSmithKline, US team up to make new drugs to combat antibiotic resistance, terror threats
	Mehr lesen zu: GlaxoSmithKline, US team up to make new drugs to combat antibiotic resistance, terror threats

Zeit

Aktuelle Nachrichten

24.05.

Glaxo Alleges Errors In Nissen's Critique Of FDA's Handling Of Avandia

Mehr lesen zu:
Glaxo Alleges Errors In Nissen's Critique Of FDA's Handling Of Avandia

23.05.

GSK flu shot may raise adult narcolepsy risk -Finnish scientists

Mehr lesen zu:
GSK flu shot may raise adult narcolepsy risk -Finnish scientists

23.05.

GSK, US HHS team up to develop drugs against antibiotic resistance and bioterrorism

Mehr lesen zu:
GSK, US HHS team up to develop drugs against antibiotic resistance and bioterrorism

22.05.

U.S. Gives Glaxo Up To $200 Million for Antibiotic Research

Mehr lesen zu:
U.S. Gives Glaxo Up To $200 Million for Antibiotic Research

22.05.

GlaxoSmithKline, US team up to make new drugs to combat antibiotic resistance, terror threats

Mehr lesen zu:
GlaxoSmithKline, US team up to make new drugs to combat antibiotic resistance, terror threats

Aktie	Kurs	%
GENMAB A/S	25,263	+0,79 %
GLAXOSMITHKLINE PLC	20,475	+1,01 %

Aktie

Kurs

GENMAB A/S

25,263

+0,79 %

GLAXOSMITHKLINE PLC

20,475

+1,01 %

GLAXOSMITHKLINE PLC	20,475 Euro	+0,205 +1,01 %
WKN: 940561 ISIN: GB0009252882 Ticker-Symbol: GS7	Xetra \| 24.05.13 \| 17:09 Uhr